GSK has announced promising results from early trials of a new gynaecological cancer drug, which it aims to fast-track for market release in the coming years. The pharmaceutical giant is
All posts tagged in GSK
16Articles
GSK has announced a significant acquisition, reaching a deal worth $950 million to purchase 35Pharma, a Canadian biopharmaceutical company with a focus on developing therapies for lung diseases linked to
Citi has increased its price target for GSK PLC (LSE:GSK, NYSE:GSK) to £22.50 whilst maintaining a neutral rating on the pharmaceutical group following a notable rally in the shares driven
GSK is evaluating potential cost-saving measures and manufacturing adjustments in Europe as it aims to invest in the launch of new products while moving away from older legacy drugs. City
GlaxoSmithKline (GSK) has announced its acquisition of a US biopharmaceutical company, RAPT Therapeutics, for a sum of 2.2 billion dollars. This strategic move marks GSK’s first bolt-on acquisition under the
Speculation surrounding a potential merger between GlaxoSmithKline and AstraZeneca has gained traction as GSK’s leadership undergoes a transition. Analysts recently suggested that the appointment of Luke Miels as GSK’s new
GSK has announced headline data from two pivotal phase III trials for bepirovirsen, a chronic hepatitis B treatment that could transform care for a disease affecting approximately 250 million people
Dame Emma Walmsley, departing chief executive of GSK, has emphasised the critical need for further improvements within the United Kingdom’s life sciences commercial environment. Speaking following the recent UK United
BAE Systems, the blue-chip defence group and FTSE 100 constituent, has secured acquisition of the former GlaxoSmithKline manufacturing plant in Ulverston, Cumbria. This deal ends a protracted period of uncertainty
Billions of pounds were added to the market value of British and global pharmaceutical companies on Wednesday following a major relief rally prompted by the Trump administration’s latest stance on
Dame Emma Walmsley has announced her departure as chief executive of GSK, marking the end of a transformative chapter for one of Britain’s most prominent pharmaceutical firms. During her tenure
GSK, one of Britain’s foremost pharmaceutical giants, has announced an ambitious plan to invest $30 billion in the United States over the coming five years. This investment will bolster research
Artificial intelligence is revolutionising pharmaceutical research, offering groundbreaking opportunities for drug discovery whilst potentially saving billions in development costs. Leading pharmaceutical giants GSK and AstraZeneca are at the forefront of
British pharmaceutical giant GSK has held firm on its annual group forecasts despite experiencing a decline in vaccine sales, with strong performance in specialist medicines helping to offset the downturn.
The Delaware Supreme Court has agreed to hear an appeal by GSK and other pharmaceutical giants, including Pfizer, Sanofi, and Boehringer Ingelheim, in their bid to halt more than 70,000
In a world where numerous industries are reevaluating the transformative potential of artificial intelligence (AI), the pharmaceutical sector is already experiencing revolutionary changes in drug discovery. Companies like GSK and
